INTRODUCTION
============

Genomic imprinting results in the differential expression of the two inherited alleles of a gene in a parent-of-origin specific manner. Imprinted genes play important roles in embryonic growth and development as well as in placental function. Genetic and epigenetic disruption of imprinted genes are also associated with a wide range of diseases, including cancer, behavioral disorders and congenital disorders ([@B1],[@B2]).

Approximately 60 genes are known to be imprinted in humans ([@B3],[@B4]). Genome-wide methods used to screen for imprinted genes have relied on the differential abundance of the maternal and paternal alleles using subtractive hybridization ([@B5],[@B6]), detection of differential expression using marker polymorphisms ([@B7],[@B8]) or transcriptome sequencing ([@B9]). Global screens for novel imprinted loci based on differential methylation between paternal and maternal alleles have also been performed, and include the use of methylation-sensitive representational difference analyses ([@B10],[@B11]) or detection of differentially methylated regions (DMRs) in the gametes ([@B12]). Each of these methods has resulted in the identification of a relatively small number of novel imprinted genes. Recently, we performed a genome-wide screen using a bioinformatics approach that resulted in the prediction of 156 candidate imprinted genes in humans ([@B13]); however, the imprint status of many of these genes has not yet been experimentally confirmed.

Perhaps the most consistent and experimentally amenable feature associated with imprinted genes is the presence of DMRs located adjacent to or within these genes. Many such DMRs are established in the gametes, the only time in development when the maternal and paternal genomes are in distinct cellular compartments. Methylation is therefore established in a manner reflecting the sex of the parental individual in which the gametes reside. This methylation pattern is normally maintained in all somatic tissues throughout life, irrespective of gene expression levels ([@B14],[@B15]). In the study described in this article, we used quantitative methylation analysis to search for novel human DMRs associated with the genes we predicted to be imprinted on chromosome 6p ([@B13]). Imprinted genes have not previously been identified at 6p, but a parent-of-origin effect in psoriasis is linked to this region of the genome ([@B16]). Loss of heterozygosity (LOH) at chromosome 6p25 is also reported in a variety of malignancies, including prostate cancer and cervical carcinoma ([@B17; @B18; @B19]). Trisomy or monosomy of 6p25 results in a variety of congenital malformations that include neuronal defects, psychomotor retardation, craniofacial defects and abnormalities in organogenesis ([@B20; @B21; @B22; @B23; @B24]). Most of these characteristics are apparent at birth, indicating important roles of the involved genes in early development.

Herein, we report the identification of a novel DMR in the 5′-region of the *FAM50B* locus (GenBank accession no.: NM_012135) at chromosome 6p25.2. *FAM50B* originated from a retrotransposon, and encodes for the protein *XAP-5*-like (*X5L*), which is highly expressed during spermatogenesis ([@B25]). We show that *FAM50B* transcripts are monoallelically expressed from the paternal allele in a variety of human tissues. Using phylogenetic comparisons in vertebrates, we found *FAM50B* to be absent in chicken and platypus, but present and biallelically expressed in the opossum and mouse. Importantly, our results also show that DMR methylation at the *FAM50B* locus is significantly reduced in testicular germ cell tumors (TGCTs), frequently resulting in the dysregulation of *FAM50B* expression, including loss of imprinting in seminomas.

MATERIALS AND METHODS
=====================

Tissues
-------

Human conceptus tissues were obtained from the National Institutes of Health-funded Laboratory of Human Embryology at the University of Washington, Seattle. Surgically resected tumor samples and the pathological diagnoses of tumor types were obtained from the Department of Pathology, Duke University Medical Center and the National Development and Research Institutes, Inc (NDRI, New York, NY, USA). Eleven TGCTs were used in this study, including two embryonal carcinomas, one seminoma mixed with embryonal carcinoma, five seminomas and three mixed germ cell tumors. Normal adult human tissues were provided by NDRI and BioChain Institute (Hayward, CA, USA). All human tissue specimens were anonymized and used under a protocol approved by the Duke University Institutional Review Board.

Gray short-tailed opossum (*Monodelphis domestica*) kidney, liver, placenta, brain and embryo samples were kindly provided by Dr Kathleen Smith (Duke University, Durham, NC, USA). Mouse liver, brain, kidney and testis samples were obtained from the F1 generation of a cross between C57BL/6J and CAST/Ei mouse strains (Jackson Laboratory, Bar Harbor, ME, USA). These animal tissues were used under protocols approved by the Duke University Institutional Animal Care and Use Committee.

Genomic DNA purification and sodium bisulfite conversion
--------------------------------------------------------

Total DNA was isolated from multiple tissues using buffer ATL, proteinase K and RNase A (Qiagen, Inc., Valencia, CA, USA) followed by phenol--chloroform extraction and ethanol precipitation. Bisulfite conversion of DNA was carried out using the Epitect Bisulfite Kit (Qiagen Inc.).

Northern blot analysis of FAM50B antisense transcript (*FAM50B-AS*)
-------------------------------------------------------------------

Northern blot analysis of total RNA from multiple human tissues was performed using Dig Northern Starter Kit (Roche Diagnostic, Indianapolis, IN, USA) according to the manufacturer's protocol. Two different probes to the antisense transcript were made using two primer pairs (FAM-18F/18R; FAM19-F/18R) respectively by PCR. T7 promoters in the primers FAM-18R and FAM19-R were used to generate DIG-labeled RNA complementary to FAM50B-AS by *in vitro* transcription. Total RNA was isolated from multiple human conceptus tissues using RNA-Stat 60 as recommended by the manufacturer (Tel-Test, Inc., Friendswood, TX, USA). Adult human total RNA was provided by BioChain Institute.

5′- and 3′-rapid amplifications of cDNA ends
--------------------------------------------

RNAs from human conceptus brain and adult testis were analyzed to locate the 5′- and 3′-termini of the *FAM50B-AS* using the 5′/3′-rapid amplifications of cDNA ends (RACE) kit according to the manufacturer's suggested protocol (second generation, Roche Diagnostics). For 5′-RACE, first-strand cDNA was generated using primer FAM-12F and purified using the Roche Diagnostics PCR Product Purification kit (Roche Diagnostics). The 5′-end of the purified cDNA was further modified by a tailing reaction. The tailed cDNA was amplified using two primers: oligo dT-anchor primer and FAM-13F. The DNA was re-amplified with a set of nested primers including the PCR anchor primer and FAM-14F ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)).

For 3′-RACE of *FAM50B-AS* RNA, first-strand cDNA was generated using the oligo dT-anchor primer. The reverse-transcribed cDNA was amplified using semi-nested PCR: the first round with the PCR anchor primer and FAM-14R, the second round with the same PCR anchor primer and FAM-15R ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). For all specimens, control reactions were performed using cDNA prepared in the absence of primers to eliminate the possibility of genomic DNA and RNA contamination. These PCR products were then sequenced on an ABI 3730 DNA sequencer (Applied Biosystems, Foster City, CA, USA).

Quantitative methylation analysis
---------------------------------

Quantitative methylation analysis of DNA in the *FAM50B* promoter was performed using MassARRAY EpiTYPER assays (Sequenom, San Diego, CA, USA). Primers for human *FAM50B* ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1), FAM-1F/1R to FAM-6F/6R) were designed using Epidesigner (Sequenom; <http://www.epidesigner.com>) to cover the CG-rich regions with amplicons in a target range of 400--600 bp. Each reverse primer was designed to contain a T7 promoter sequence tag (5′-CAG TAA TAC GAC TCA CTA TAG GGA GAA GGC T-3′) for *in vitro* transcription, and each forward primer incorporated a 10-mer tag (5′-AGG AAG AGA G-3′) to balance the primer annealing temperature with that of the primer containing the T7 tag. Polymerase chain reaction amplification was performed using HotStarTaq (Qiagen, Inc.) with the following parameters: polymerase activation at 95°C for 5 min, followed by denaturation at 94°C for 20 s, annealing at 60°C for 25 s and extension at 72°C for 1 min for a total of 40 cycles, with a final incubation at 72°C for 5 min. After dephosphorylation of unincorporated dNTPs, the processed PCR products were used in *in vitro* transcription reactions (T-cleavage assay) according to the manufacturer's standard protocol (Sequenom). The transcription products were conditioned to remove bilvalent cation adducts by dilution with 20 µl H~2~O and addition of 6 mg of Clean Resin (Sequenom). The samples were then spotted on a 384-pad Spectro-CHIP (Sequenom) using a MassARRAY Nanodispenser (Samsung, Irvine, CA, USA), followed by spectral acquisition on a MassARRAY analyzer compact MALDI-TOF MS (Sequenom). Fragments containing CpG sites were analyzed with EpiTyper software (Sequenom) to generate quantitative methylation fractions at these sites. The MassARRAY analysis was repeated three times for each sample and the results were averaged.

Bisulfite sequencing of cloned alleles
--------------------------------------

Genotyping of rs2239713 in the *FAM50B* promoter region was carried out to allow for allele-specific determination of methylation status. PCR was performed with primers FAM-7F and FAM-7R ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)), followed by BigDye sequencing (Applied Biosystems) on an ABI 3730 DNA sequencer (Applied Biosystems). The sense DNA sequence was amplified from bisulfite converted genomic DNA from conceptus tissues using primers FAM-2F and FAM-4R. The antisense DNA sequence of heterozygous individuals was amplified from bisulfite converted genomic DNA from conceptus tissues and sperm specimens using the following primers: FAM-8F and FAM-8R. PCR products were directly ligated into the PCR® 2.1 vector using the TOPO TA Cloning Kit (Invitrogen). Clones for each specimen were directly sequenced using an ABI BigDye Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems) on an ABI 3730 DNA sequencer (Applied Biosystems).

Genotyping and imprinting expression analyses in human tissues
--------------------------------------------------------------

Each individual was genotyped for polymorphism rs6597007 in *FAM50B* by sequencing genomic DNA. Genotyping was carried out by PCR with primers FAM-9F and FAM-9R, followed by BigDye sequencing (Applied Biosystems) on an ABI 3730 DNA sequencer (Applied Biosystems). RNA from heterozygous individuals was analyzed to determine whether expression was monoallelic or biallelic. Total RNA was isolated from multiple human tissues using RNA-Stat 60 as recommended by the manufacturer (Tel-Test, Inc., Friendswood, TX, USA). First-strand cDNA was synthesized from Dnase I-treated RNA using Superscript II (Invitrogen), as recommended by the manufacturer using gene-specific primer FAM-10R. PCR was performed for 40 cycles with primers FAM-9F and FAM-9R. For all specimens, control reactions were performed using cDNA prepared in the absence of reverse transcriptase to eliminate the possibility of genomic DNA contamination. The PCR products were gel-extracted (GenElute, Sigma Chemical Co, St Louis, MO, USA) and directly sequenced on an ABI 3730 DNA sequencer (Applied Biosystems).

Allele-specific expression of *FAM50B* and *FAM50B-AS* transcripts
------------------------------------------------------------------

Strand-specific RT--PCR was performed to distinguish between *FAM50B* and *FAM50B-AS* for allele-specific expression using SNP rs6597007. First strand cDNA was generated from Dnase I-treated RNA from human tissues using the oligo dT-anchor primer and the 3′-RACE kit as described above. For detection of *FAM50B* transcripts, PCR was performed using primer FAM-9F and the PCR anchor primer. For detection of *FAM50B-AS*, PCR was first performed using primer FAM-14R and the PCR anchor primer, followed by nested PCR using primers FAM-15F and FAM-9R.

SNP rs3196512 was used to determine allelic expression of *FAM50B* in TGCTs. Genotyping of genomic DNA was carried out by PCR with primers FAM-11F and FAM-11R followed by sequencing. Individuals heterozygous for polymorphism rs3196512 were further analyzed to distinguish between monoallelic and biallelic expression. First strand cDNA was generated from Dnase I-treated RNA using the oligo dT-anchor primer as described above. RT--PCR was performed using primer FAM-11F and the PCR anchor primer.

For all specimens, control reactions were performed using cDNA prepared in the absence of primers to eliminate the possibility of genomic DNA and non-specific RNA contamination. These PCR products were sequenced directly. Sequences for all primers used are provided in [Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1).

Relative quantitative RT real-time PCR analysis of *FAM50B and FAM50B-AS*
-------------------------------------------------------------------------

Relative quantification of both *FAM50B* and *FAM50B-AS* mRNA expression levels was performed on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems). First-strand cDNA synthesis was performed with an oligo dT primer on Dnase I-treated RNA. Real-time reactions were carried out in duplicate with QuantiFast SYBR Green PCR Master Mix (Qiagen, Inc.) in a total reaction volume of 20 µl, using thermal conditions recommended by the manufacturer. For detection of *FAM50B* transcripts, real-time PCR was performed using primers FAM-16F and FAM-16R. For detection of *FAM50B-AS* transcript levels, real-time PCR was performed using primers FAM-17F and FAM-17R that anneal to sequence within intron 1 of *FAM50B*. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous RNA control. Target and endogenous control amplifications were carried out in separate tubes. Results were analyzed using SDS RQ Manager 1.2 software. Each ΔCt value (Δ*C*~t~ = *C*~t~ target − *C*~t~ control) was transformed to a percentage (percent target = 2^−Δ^*^Ct^* × 100).

Analysis of opossum and mouse *FAM50B* orthologs
------------------------------------------------

Opossum and mouse were screened for genomic DNA polymorphisms by PCR amplification using primer pairs ([Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1), Opossum-1F/1R to -3F/3R; Mouse-1F/1R to -3F/3R) covering the entire coding region, followed by sequencing. Total RNA was isolated from multiple tissues of heterozygotes by homogenization in RNA-Stat 60 (Tel-Test). First strand cDNA was synthesized from Dnase I-treated RNA using strand-specific primers ([Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1), Opossum-RT; Mouse- RT). cDNA fragments amplified with primers Opossum-1F/1R and Mouse-4F/4R were purified, and directly sequenced on an ABI 3730 DNA sequencer (Applied Biosystems). Quantitative DNA methylation analysis of the *FAM50B* promoter was performed using MassARRAY EpiTYPER assays as described above (primers shown in [Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1), Opossum-4F/4R to -7F/7R and Mouse-5F/5R to -18F/18R).

Statistical analysis
--------------------

Statistical analysis was carried out using GraphPad Prism 5 software (GraphPad Software, Inc.; La Jolla, CA, USA). Average CpG methylation and expression between TGCTs and control tissues were compared by ANOVA and *t*-test. Results were considered statistically significant at the 5% significance level.

RESULTS
=======

Identification *of FAM50B* antisense transcripts
------------------------------------------------

Many imprinted genes are associated with non-coding RNAs, often taking the form of antisense transcripts ([@B26],[@B27]). We therefore tested the candidate imprinted gene *FAM50B* ([@B13]) for the presence of an antisense transcript using northern blot analysis and RACE. Such a transcript was detected at this locus, and hereafter referred to as *FAM50B* antisense (*FAM50B-AS*) ([Figure 1](#F1){ref-type="fig"}A and [Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). Using RNA probes specific to the putative FAM50B-AS sequence, an appropriately sized band (∼1.7 kb) was detected by northern blotting, with probes to different sequences in FAM50B-AS detecting the same band ([Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). We then identified the 5′-end of *FAM50B-AS* at +1506 relative to the *FAM50B* translational start codon ([Figure 1](#F1){ref-type="fig"}C). This is also the nucleotide position where the sense strand mRNA terminates (GenBank accession no.: NM_012135.1). The results from 3′-RACE demonstrated the terminus of *FAM50B-AS* occurs within intron 1 of *FAM50B*, at position −237 relative to the translational start codon for *FAM50B*. Also, when sequencing the RT--PCR product of 3′-RACE, the polyA sequence is evident ([Figure 1](#F1){ref-type="fig"}B) in addition to a correctly positioned consensus AAUAAA motif that has been shown to be essential for cleavage and polyadenylation (27 nt upstream, within the 10--30 nt range; underlined, [Figure 1](#F1){ref-type="fig"}B) ([@B28]). A CA dinucleotide motif which defines the polyadenylation site for most genes is also present at the polyadenylation site identified for the *FAM50B-AS*. These results confirm the presence of FAM50B-AS with length of 1743 bp. Figure 1.Genomic map of human *FAM50B* locus. (**A**) *FAM50B-AS* RACE-PCR showing a 211 bp product of 5′-RACE and an 823 bp product of 3′-RACE. M, 100 bp DNA ladder. N, control reactions were performed using cDNA prepared in the absence of primers to eliminate the possibility of genomic DNA and RNA contamination. (**B**) Sequencing of 3′-RACE-PCR demonstrates the polyA sequence and AAUAAA motif (underlined) of *FAM50B-AS.* (**C**) The *FAM50B* locus spans 2 kb of genomic sequence at chromosome 6p25 and consists of two exons (E1 and E2). Horizontal arrows indicate the sense (*FAM50B*) and antisense (*FAM50B-AS*) transcripts of the gene. *FAM50B-AS* originates at the 3′-end of *FAM50B* and terminates within *FAM50B* intron 1. The black horizontal line indicates the position of the DMR. Vertical arrows designate positions of SNPs rs2239713 (C/T), rs6597007 (G/C), rs3196512 (G/C) and the translational start codon ATG. The position and direction of primers used for RACE is indicated by horizontal arrowheads. Primer sequences are provided in [Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1).

Identification of a *FAM50B*-associated DMR
-------------------------------------------

Many imprinted genes are associated with CpG-rich regions that exhibit differential methylation of the maternal and paternal alleles. For detection of DMRs, regions are identified for which multiple CpG sites show a methylated to unmethylated ratio of ∼1:1, a pattern consistent with DNA methylated on only one chromosome. To identify potential DMRs, we used the Sequenom MassARRAY Epityper (Sequenom) for quantitative DNA methylation analysis on bisulfite treated DNA. Validation tests on previously identified DMRs of known imprinted genes (*PEG3*, *NAP1L5* and *MEG3*), showed methylation of 30--60% for these regions (unpublished data).

We then searched genomic regions 10-kb upstream and downstream of the candidate imprinted gene *FAM50B* for GC rich regions (G + C \>40%). We identified a CpG island spanning the *FAM50B* promoter and most of the gene (−1353 to +1066 relative to the translational start codon; Chr6: 3848692-3851100, Version February 2009: GRCh37/hg19; [Figure 1](#F1){ref-type="fig"}B). We quantified methylation at the 166 CpG sites within this region in human conceptus liver (*n* = 3) and brain (*n* = 3). The core region, from the 12th CpG to 110th CpG (−884 bp to +415 bp relative to the translational start codon), was 30% to 60% methylated in these tissues, whereas the CpG sites in the 5′- and 3′-boundary regions were more highly methylated ([Figure 2](#F2){ref-type="fig"}A). These findings indicate the existence of a candidate DMR in the core region. Figure 2.CpG methylation status at the *FAM50B* locus. (**A**) The percent methylation of CpG sites 1--166 was quantified by Sequenom MassARRAY using DNA from conceptus liver (blue line, *n* = *3*) and brain (red line, *n* = *3*). CpG site numbers correspond to the positions within the GC rich region (−1353 to +1066 relative to the *FAM50B* translational start codon). Arrow indicates the position of the translational start codon. The location of a DMR is shown by a horizontal line. (**B**) Average methylation of CpG sites (12 to 110) does not vary significantly for conceptus tissues from the three germ layers and from different gestational ages, while sperm shows low levels of methylation at this locus. B, brain; L, liver; K, kidney; P, placenta; S, sperm; B1, L1 and K1---gestational age of 81 days; B2, L2 and K2---gestational age of 110 days.

The average methylation in brain, liver and kidney conceptus tissues (gestational ages 81 and 110 days) did not significantly vary for the region from the 12th to 110th CpG (*P* = 0.12, *n* = 2, ANOVA) ([Figure 2](#F2){ref-type="fig"}B). We also determined the degree of methylation for this region in ejaculated spermatozoa (*n* = 2) and found that it was strikingly hypomethylated in comparison to the somatic tissues analyzed ([Figure 2](#F2){ref-type="fig"}B). These findings indicate that the methylation observed in this region is either derived from the oocyte, or is established post-fertilization.

To determine if the DNA methylation present in this region is allele-specific, we performed bisulfite sequencing of individual cloned alleles from human conceptus liver (*n* = 2). These sequences showed that CpG sites in this region for any cloned allele were either completely methylated or unmethylated ([Figure 3](#F3){ref-type="fig"}A). These findings are consistent with this region comprising a DMR of ∼740 bp that is likely involved in regulating imprinting at the *FAM50B* locus. We also used the single nucleotide polymorphism rs2239713, which is located between CpG sites 20 and 21, to distinguish between the parental alleles. On the sense strand, SNP rs2239713 is a C/T polymorphism that is indistinguishable following bisulfite conversion, so we instead designed primers to analyze the complementary DNA strand, where the polymorphism is present as a G or A. Analysis of bisulfite-modified DNA from three individual conceptus liver tissues of individuals heterozygous for this SNP who have homozygous G/G mothers showed that methylation is allele specific, with the maternally derived G allele fully methylated and the paternally derived A allele fully unmethylated ([Figure 3](#F3){ref-type="fig"}B). Bisulfite sequencing of cloned alleles of mature sperm DNA (*n* = 2) showed a complete lack of methylation in this region ([Figure 3](#F3){ref-type="fig"}C), consistent with the previously described quantitative analysis. These results confirm the presence of a DMR with maternal DNA methylation at the *FAM50B* locus. Figure 3.Allele-specific methylation at the *FAM50B* locus. (**A**) Clones obtained from bisulfite-treated conceptus liver DNA are either predominantly methylated or unmethylated from the 18th CpG site to the 66th CpG site. (**B**) Clones obtained from bisulfite-treated conceptus liver DNA, representing one of three individuals heterozygous for SNP rs2239713 (arrow), while their matched maternal deciduae are homozygous G/G for the SNP sites. The allele-specific distribution of methylation with respect to the G/A polymorphism demonstrates that the maternally-derived allele is methylated while the paternally derived allele is unmethylated. (**C**) Clones obtained from bisulfite-treated mature sperm DNA are completely unmethylated. CpG sites are represented by circles. Unfilled circle, unmethylated CpG site; filled circle, methylated CpG site.

Imprinting and expression analysis of the *FAM50B* locus in human tissues
-------------------------------------------------------------------------

To determine if transcripts associated with the *FAM50B* locus are monoallelically expressed during early development, RT--PCR was performed followed by nucleotide sequencing of the cDNA in a panel of conceptus tissues from multiple individuals with gestational ages ranging from 81 to 113 days. We analyzed a 206 bp region containing a single nucleotide polymorphism (rs6597007) located in exon 2. For human conceptuses showing heterozygosity at the polymorphic site, monoallelic expression of *FAM50B* was observed in nearly all fetal tissues analyzed including brain (*n* = 5), liver (*n* = 5), placenta (*n* = 6), adrenal gland (*n* = 2), kidney (*n* = 1), heart (*n* = 1) and testis (*n* = 2), while expression was biallelic in the ovary (*n* = 1) ([Figure 4](#F4){ref-type="fig"}). Furthermore, RT--PCR followed by nucleotide sequencing of cDNA from adult testis (*n* = 1) and liver (*n* = 1) from individuals heterozygous for SNP rs6597007 demonstrated that *FAM50B* monoallelic expression was maintained in adulthood ([Supplementary Figure S2A](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). Figure 4.Imprinting analysis of human *FAM50B*. Genomic DNA from human conceptuses (**A** and **B**) is heterozygous for polymorphism rs6597007 (G/C). Sequencing of cDNA demonstrates monoallelic expression of *FAM50B* transcripts in multiple conceptus tissues, including brain, liver, placenta, adrenal gland, kidney, heart and testis. In contrast, *FAM50B* expression is biallelic in fetal ovary. The position of SNP rs6597007 used to determine allelic expression is indicated by the arrows.

Matched maternal decidual tissues of informative conceptuses were genotyped to determine the parental origin of the expressed *FAM50B* allele in humans. DNA from the maternal decidua for a conceptus polymorphic at site rs6597007 (G/C) was homozygous C/C for this SNP ([Supplementary Figure S2B](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). Transcripts in the conceptus were derived only from the allele containing G at this SNP position, indicating paternal expression. Identical results for parental allele-specific expression were obtained for three additional matched sets of decidua and conceptus tissues, demonstrating that only the paternally inherited allele was expressed.

To determine if both the *FAM50B* and *FAM50B-AS* transcripts are monoallelically expressed, we performed strand-specific RT-PCR by amplifying the 3′-end of *FAM50B* and *FAM50B-AS* containing SNP rs6597007 using 3′-RACE-derived cDNA ([Supplementary Figure S3A](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). We demonstrated that the *FAM50B* sense and antisense transcripts were both monoallelically expressed from the same allele in conceptus brain (*n* = 1), adult liver (*n* = 1) and adult testis (*n* = 1) ([Figure 4](#F4){ref-type="fig"} and [Supplementary Figures S2 and S3B](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)).

The level of expression of *FAM50B* and *FAM50B-AS* in human tissues was determined by relative quantitative RT--PCR using cDNA derived from a panel of conceptus and adult tissues (*n* = 2). *FAM50B* exhibits the highest expression in pre- and post-natal testis tissue, while *FAM50B-AS* expression is highest in conceptus testis and brain ([Supplementary Figure S4A and S4B](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)).

Analysis of genes neighboring *FAM50B* in human tissues
-------------------------------------------------------

Imprinted genes are often present as gene clusters in the genome. We therefore determined if genes neighboring *FAM50B* also exhibit imprinted expression. In the human genome, there are six genes in a 200 kb region centered around *FAM50B*. The three pseudogenes, *RPS25P7*, *TDGF4* and *LOC728344* are not transcribed, and there are no annotated SNPs useable for allele-specific expression analysis of *LOC100289494* and *LOC100289591*. The remaining gene, *C6orf145*, was analyzed for allele-specific expression, and we found that both parental alleles were expressed at approximately equivalent levels from all conceptus tissues analyzed, including brain (*n* = 3), heart (*n* = 1), kidney (*n* = 2), muscle (*n* = 2), lung (*n* = 1) and placenta (*n* = 5) ([Supplementary Figure S5](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1), SNP rs226959) These findings cannot, however, exclude the possibility that *C6orf145* is imprinted in a highly tissue- and/or developmental stage-specific manner.

Evolutionary analysis of *FAM50B*
---------------------------------

*FAM50B*, also known as *XAP-5* like gene (*X5L*), encodes a 325 amino acid (AA) protein and arose from the X-linked *XAP-5* gene, most likely by retrotransposition ([@B25]). XAP-5 is a conserved protein found in a wide range of eukaryotes ranging from the roundworm (*Caenorhabditis elegans*) to the human. Amino acid alignment of *XAP-5* and *X5L* demonstrates that they are 77% identical in the human.

To determine the timing of the retrotransposition event responsible for creating the *FAM50B* locus during vertebrate evolution, we compared the region encompassing *FAM50B* in human and mouse (Eutherian), opossum (Metatherian), platypus (Prototherian) and chicken (Aves) using the UCSC and Ensembl genome browsers (<http://genome.ucsc.edu> and <http://www.ensembl.org/>, respectively). In the mouse, *FAM50B* is near *C6orf145* and between *SLC22A23* and *PRPF4B* ([Figure 5](#F5){ref-type="fig"}). It encodes a 334 AA protein with 83% sequence similarity to the human ortholog. BLAST analysis of the platypus and opossum genomes (<http://www.ncbi.nlm.nih.gov/Genomes>) showed that the opossum, but not the platypus, contains a gene orthologous to *FAM50B*. Unlike mouse and human, the opossum *FAM50B* ortholog is not located between *SLC22A23* and *PRPF4B*, but rather resides 78 Mb from the 3′-end of *SLC22A23*. The opossum *FAM50B* gene also has an intronless open reading frame, and encodes a 338 AA protein (Gene ID: LOC100027108; GenBank accession no.: XM_001370796) with 76% similarity to the human ortholog. Interestingly, both *FAM50B* and *C6orf145* are absent in the chicken genome. These findings are consistent with *FAM50B* having undergone retrotransposition from the X chromosome source gene after Therians split from Prototherians. Figure 5.Phylogenetic comparison of the genomic structure of *FAM50B* and flanking genes. *FAM50B* is flanked by *C6orf145* and *PRPF4B* in human (chromosome 6) and mouse (chromosome 13), but is 78 Mb upstream from the *SLC22A23* ortholog in the opossum (chromosome 3). *FAM50B* orthologs are not present in the platypus (UltraContig Ultra 352) and chicken genomes (chromosome 2).

As in the human and mouse, *FAM50B* is located between *C6orf145* and *PRPF4B* (SuperContig Scaffold54 from Ensembl genome browser) in the African elephant (*Loxodonta africana*), a member of the most ancestral placental super order, Afrotheria. Thus, *FAM50B* appears to have integrated into the genomic region between *C6orf145* and *PRPF4B* after the divergence of marsupials from ancestral Eutherian mammals.

We determined that transcripts from the opossum *FAM50B* ortholog have high levels of expression in kidney, liver, embryo and placenta, but expression was not detected in the brain ([Supplementary Figure S6A](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). Transcripts of the mouse *FAM50B* ortholog were expressed in liver, kidney, brain and testes ([Supplementary Figure S6B](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). Nevertheless, expression of *FAM50B* in the opossum ([Figure 6](#F6){ref-type="fig"}A) and mouse ([Figure 6](#F6){ref-type="fig"}C) was biallelic in all tissues investigated. We did not test for the presence of an antisense transcript in the opossum and mouse. Moreover, CpG methylation of the genomic region orthologous to the DMR in the human is comparatively hypomethylated in the opossum ([Figure 6](#F6){ref-type="fig"}B), and hypermethylated in the mouse ([Figure 6](#F6){ref-type="fig"}D). Figure 6.Imprinting analysis of *FAM50B* in the opossum and the mouse. (**A**) cDNA sequencing demonstrates biallelic expression of *FAM50B* in opossum placenta and liver. Arrows indicate the position of the SNP used to determine the allelic expression patterns. (**B**) Methylation at CpG dinucleotides is \<20% for most of the region that encompasses the opossum *FAM50B* translational start codon, from −340 to 972 bp. Blue line, DNA from liver; red line, DNA from kidney. Arrow indicates the position of the translational start codon. (**C**) *FAM50B* cDNA sequencing demonstrates biallelic expression of the *FAM50B* in mouse brain and testis. Arrows indicate the position of the SNP used to determine the allelic expression patterns. (**D**) Methylation is \>60% at most CpG sites in proximity to the translational start codon of murine *FAM50B* (from −8800 to 1120 bp relative to translational start codon). Arrow indicates the position of the translational start codon. Blue line, DNA from kidney; red line, DNA from liver.

Loss of the methylation imprint in human TGCTs
----------------------------------------------

DMR methylation and allele-specific expression of *FAM50B* in TGCTs was determined to assess the role of this gene in cancer formation ([Figure 7](#F7){ref-type="fig"}A). Methylation of the *FAM50B* DMR was significantly reduced (*P* \< 0.001, unpaired *t*-test) in 10 of 11 TGCTs specimens we investigated, including two embryonic carcinomas (C1, 5.1 ± 3.9%; C2, 25.8 ± 7.0%) one seminoma mixed with embryonic carcinoma (SC1, 14.5 ± 5.3%), five seminomas (S1, 4.5 ± 2.8%; S2, 8.1 ± 3.8%; S3, 11.7 ± 4.3; S4, 6.2 ± 4.7%; S5, 21.0 ± 7.0%) and mixed germ cell tumors (M2, 15.7 ± 8.4%; M3, 24.2 ± 6.5%) relative to that in normal testis (TN, 36.6 ± 7.7%, *n* = 3). DMR methylation was not significantly altered in a mixed germ cell tumor (M1, 32.4 ± 14.7%; *P* = 0.07). Figure 7.Methylation status and gene expression of *FAM50B* locus in TGCTs. (**A**) Percent methylation of the *FAM50B* DMR in each tumor and in normal testis controls (*n* = 3). (**B**) Relative expression levels, normalized to *GAPDH*, of *FAM50B* transcripts in TGCTs and in normal testis controls (*n* = 3). (**C**) Relative expression levels, normalized to *GAPDH*, of the *FAM50B-AS* transcripts in TGCTs and in normal testis controls (*n* = 3). TGCTs include: embryonic carcinoma (C1, C2), seminoma mixed with embryonic carcinoma (SC1), pure seminoma (S1, S2, S3 and S4, S5), and mixed germ cell tumor (M1, M2 and M3). Normal testis tissue (TN, *n* = 3) was used for comparison.

Quantitative PCR demonstrated that the decreased level of methylation at the *FAM50B* DMR in TGCTs was frequently associated with a reduced level of *FAM50B* and *FAM50B*-AS expression ([Figure 7](#F7){ref-type="fig"}B and C). Only seminoma S3 demonstrated a significant increase in expression of both *FAM50B* (*P* \< 0.001) and *FAM50B-AS* (*P* = 0.002) relative to that in normal testis. These findings indicate that DMR methylation status alone is insufficient for regulation of *FAM50B* and *FAM50B-AS* transcript levels in some TGCTs.

To determine if *FAM50B* imprinting is maintained in TGCTs, we analyzed tumors heterozygous for SNP rs3196512 (C/G), which included embryonic carcinomas C1 and C2, seminomas S2 and S3, and mixed germ cell tumors M2 and M3, to distinguish the allelic expression pattern for the *FAM50B* transcript. We also analyzed the seminoma mixed with embryonic carcinoma (SC1), which is heterozygous for SNP rs6597007 (C/G), to determine the allelic expression pattern for both the sense (S) and antisense (AS) transcripts ([Figure 8](#F8){ref-type="fig"}). In the embryonic carcinomas (C1 and C2) and mixed germ cell tumors (M2 and M3) investigated, monoallelic expression of *FAM50B* was maintained ([Figure 8](#F8){ref-type="fig"}A); however, in the seminomas (S2 and S3) both alleles of *FAM50B* were expressed ([Figure 8](#F8){ref-type="fig"}B). Furthermore, both alleles of *FAM50B* and *FAM50B-AS* were expressed in the seminoma mixed with embryonic carcinoma (SC1) ([Figure 8](#F8){ref-type="fig"}B). These results indicate that loss of imprinting at the *FAM50B* locus is a common event in seminomas. Figure 8.Allelic expression of *FAM50B* in TGCTs. (**A**) cDNA sequencing of TGCTs demonstrates maintenance of monoallelic expression of the *FAM50B* transcript in embryonic carcinoma C1 and C2 and mixed germ cell tumor M2 and M3. (**B**) cDNA sequencing of TGCTs demonstrates biallelic expression of the *FAM50B* transcripts in the seminomas S2 and S3 and biallelic expression of both *FAM50B* and *FAM50B-AS* in seminoma mixed with embryonic carcinoma SC1. The SNP rs3196512 (G/C) was used to determine allelic expression of *FAM50B* in sample C1, C2, M2, M3, S2 and S3. The SNP rs6597007 (G/C) was used to determine allelic expression of *FAM50B* and *FAM50B-AS* in sample SC1. The position of the SNP used to determine allelic expression is indicated by the arrows.

To determine if the DNA methylation in the DMRs is involved in regulating imprinting of the *FAM50B* locus, we performed bisulfite sequencing of individual cloned alleles of S2 ([Supplementary Figure S7A](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)) and S3 ([Supplementary Figure S7B](http://nar.oxfordjournals.org/cgi/content/full/gkr108/DC1)). Our results showed that allele-specific methylation was partially lost in S2 and S3. These results were associated with the loss of imprinted expression of *FAM50B* transcripts in seminomas, indicating that this DMR is required for maintaining the imprinted status of this gene.

DISCUSSION
==========

In our search for imprinting regulatory regions on chromosome 6p, we identified a novel DMR at the *FAM50B* locus, a gene we previously predicted to be imprinted (13). The unique parent-of-origin-dependent expression of imprinted genes is in large part regulated by the methylation status of associated DMRs. There are two distinct types of DMRs that regulate the expression of genomically imprinted genes: germline DMRs that are established during gametogenesis and somatic DMRs that are formed post-fertilization, sometimes in a tissue-specific manner ([@B29]). Using the Sequenom MassARRAY system, we performed methylation analysis at the *FAM50B* locus in human tissues derived from the three germ layers. These methylation analyses, combined with those of mature human spermatozoa, identified a novel DMR at the promoter region of *FAM50B*. The *FAM50B* DMR showed uniform differential methylation in embryonic tissues of different germ layer origin. It was maternally methylated in conceptus liver and unmethylated in sperm. Thus, this DMR is either a maternal methylation imprint mark established in oocytes or it is acquired post-fertilization. Our results therefore support the use of the Sequenom MassARRAY as an effective tool for experimentally identifying novel DMRs of imprinted genes.

We identified both sense and antisense transcripts of *FAM50B*, and confirmed the imprint status of both, with each transcript displaying paternal expression in normal human tissues. Thus, we demonstrated for the first time that *FAM50B* is an imprinted gene in humans. The function of the gene products from both *FAM50B* and its X-linked resource gene *XAP-5* are currently unknown. However, phylogeny indicates related genes with XAP5 domains in both *Brassica* and *Arabidopsis*, indicating that the origin of *FAM50*-related genes occurred early in the development of eukaryotes. Hints as to function may come from *Arabidopsis XCT* (XAP-5 circadian timekeeper), which regulates the circadian clock in response to light, acting as a global regulator of growth ([@B30]).

*XAP-5* contains runs of CG-rich trinucleotide repeats (CCG) in the 5′-untranslated region, and therefore is considered a candidate disease gene ([@B31]); however, this triplet repeat is not present in *FAM50B*. We found high expression of *FAM50B* in embryonic tissues, indicating an important role in prenatal development. We also found that *FAM50B* is highly expressed in testis, consistent with the prior observation that X-derived retrogenes are more frequently expressed in spermatocytes than autosomally-derived retrogenes ([@B32]).

A considerable proportion of imprinted genes produce both sense and antisense transcripts, which was our impetus for searching for a *FAM50B* antisense transcript. Non-coding antisense transcripts are broadly classified into large non-coding RNAs and small regulatory RNAs, acting in *cis* or in *trans*, respectively, to repress the flanking protein-coding imprinted genes ([@B26],[@B27]). *FAM50B-AS*, together with *IGF2AS* (*IGF2* antisense) ([@B33]), *APEG*3 (*PEG3* antisense) ([@B34]), *SLC22A18AS* (*SLC22A18* antisense) ([@B35]) and *PEG1*-AS (*PEG1* antisense) ([@B36]), may be more suitably classified into a new RNA group due to their specific features. First, all are paternally expressed from the same allele with their sense transcripts, which differs from the reciprocal imprinting pattern of large and small non-coding RNAs (for example, paternally expressed antisense *Air* and maternally expressed sense *IGF2R*; and maternally expressed miRNA *MiR*-431 and paternally expressed sense *RTL1*). Second, the length of the antisense transcripts is 1--2.5 kb, much shorter than the large non-coding RNAs (usually 10--100 kb), but much longer than the small non-coding RNAs (\<300 bases). The biological functions of these antisense transcripts, whether involved in regulating the imprinting of their sense transcripts or in maintaining normal tissue function, remain elusive. Interestingly, imprinted *FAM50B-AS* exhibits the highest level of expression in fetal brain, indicating that *FAM50B-AS* is potentially involved in preserving normal brain function.

Multiple transcribed and functional retrotransposed genes that originated from X-linked housekeeping genes have been uncovered in the genomes of mammals ([@B37],[@B38]). The percentage of expressed retrotransposons that originate from X chromosome genes is higher than those originating from autosomal chromosomes. Five of these X-derived retrotransposed genes in mice (i.e. *MCTS2, NAP1L5, U2AF1-RS1, Inpp5f_v2* and *Peg12*) and three orthologues in humans (i.e. *MCTS2*, known as *PSIMCT-1, INPP5F_V2* and *NAP1L5*) are known to be imprinted, and all are paternally expressed ([@B39],[@B40]). In contrast, *KLF14* retrotransposed from an autosomal chromosome, and is maternally expressed ([@B41]). Of particular interest is *RB1*, which is not a retrotransposed gene; however, the preferential maternal expression of the *RB1* transcript and the paternal expression of an alternative transcript of this gene is linked to a retrotransposed pseudogene derived from an autosomal chromosome ([@B42]). In the case of *RB1*, the pseudogene is not transcribed, but rather acts as a weak promoter for an alternate *RB1* transcript, regulated by a DMR in the pseudogene ([@B43]). Clearly, retrotransposed elements play an important role in parental allele silencing of imprinted genes. It has been hypothesized that the retrotransposition of X-derived genes is a mechanism to insure continued activity for essential genes that are otherwise silenced by transient X-chromosome inactivation during spermatogenesis ([@B32],[@B44]). *FAM50B* is another example of a maternally silenced imprinted gene derived from an X-linked gene by retrotransposition. This adds further support to the hypothesis that imprinting functions in part as a dosage compensation mechanism ([@B45]). However, unlike other known retrotransposed imprinted genes, *FAM50B* is not located within an intron of a host gene.

Comparison of X-inactivation and retrotransposed genes between marsupials and eutherians may be highly informative for understanding the evolution of imprinted gene silencing, especially with regard to the idea that retrotransposition of X-linked genes compensates for X-inactivation during spermatogenesis. The recent discovery of X-chromosome inactivation during spermatogenesis in opossum has led to a model for the origins of X-chromosome silencing for dosage compensation in females. In female marsupials, it is always the paternal X chromosome that is silenced. Persistence of X-inactivation that was originally established during spermatogenesis might explain this paternal-specific X chromosome silencing in females. If this is the ancestral method of mammalian X-inactivation, then the reactivation and subsequent random inactivation seen in eutherians is a modification of the simpler marsupial mechanism, possibly providing resiliency by not forcing dependency on one X chromosome ([@B46]).

It may be possible to elucidate the mechanism by which retrotransposed imprinted genes acquired parent-of origin expression by investigating their evolution in mammals. Only a small number of imprinted genes in eutherians are also monoallelically expressed in marsupials ([@B47]), and none of the known eutherian imprinted genes that originated from retrotransposition events are imprinted in marsupials. The imprinting of *MCTS2, INPP5F_V2* and *NAP1L5* is conserved in the human and mouse, indicating retrotransposition occurred before radiation of the human and rodent lineages ([@B42]). *U2af1-rs1* and *Peg12* are postulated to have been created by retrotransposition during mouse evolution after the divergence of mice and humans since their orthologs are not present in the human ([@B48]). Phylogenetic comparison of the orthologs of the *FAM50B* locus indicates that this gene was integrated into the opossum genome in a position different from that in human, mouse and elephant. Although it is expressed in a variety of opossum tissues, we showed that *FAM50B* is not imprinted in the opossum. Furthermore, *FAM50B* in the mouse does not contain a DMR in the promoter region, and it is also not imprinted. Hence imprinted expression of human *FAM50B* appears to have originated from a species-specific retrotransposition event that occurred subsequent to the radiation of the human and rodent lineages. These findings demonstrate that the repertoires of imprinted genes vary between species, which is consistent with previous reports indicating that imprinted genes did not arise at a single point during evolution ([@B49]).

To obtain insight into the importance of *FAM50B* in normal spermatogenesis, we analyzed its methylation profile and expression pattern in seminomatous and non-seminomatous TGCTs. TGCTs have a pluripotent nature and display histology reflecting that of primordial germ cells (PGCs) to embryonal and somatic cell differentiation. Seminomas recapitulate some aspects of spermatogenesis, whereas non-seminomas demonstrate embryonal and extraembryonal differentiation patterns ([@B50]). Besides histological distinctions, they have epigenetic differences. Seminomas have widespread hypomethylation, both in CpG islands and globally, unlike non-seminomas, which have higher methylation overall ([@B51]). This hypomethylation is a significant similarity between seminomas and PGCs, which also have very low methylation levels. All these similarities distinguish seminomas from other types of TGCTs, and suggest that seminomas originate from a more primitive, less differentiated cell type that may be more prone to tumorigenesis.

The *FAM50B* DMR showed hypomethylation in seminomatous and the majority of non-seminomatous TGCTs; however, complete loss of imprinted expression of *FAM50B* and *FAM50B-AS* was only observed in seminomas. Although hypomethylation of the reciprocally imprinted genes, *H19* and *IGF2*, is also observed in TGCTs, null expression, monoallelic expression and biallelic expression of these genes are observed in both seminomatous and non-seminomatous TGCTs ([@B52],[@B53]). Thus, the methylation status of the DMR for *H19* and *IGF2* is not always correlated with their allelic expression. Similarly, imprinted gene expression at the *FAM50B* locus is not always associated with the methylation status of its DMR in non-seminomatous TGCTs. This indicates that factors other than methylation may contribute to transcriptional regulation of imprinting of *FAM50B* in non-seminomatous TGCTs. In support of this idea, a recent study suggests that histone methylation may act as the principal regulator of gene expression in non-seminomas ([@B54]). Determination of histone modifications at the *FAM50B* locus may help clarify the mechanism regulating imprinted expression of *FAM50B* in non-seminomatous TGCTs. Analysis of copy number variations in TGCTs has also been extensively studied ([@B55]). A number of chromosomal aberrations have been observed, but none of them are associated with the 6p25 locus containing *FAM50B*. Additionally, the similarities of seminomas to undifferentiated PGCs suggest that seminomas have reduced epigenetic regulation besides the observed hypomethylation, which would be consistent with the loss of *FAM50B* imprinting in only this tumor type. The high frequency of loss of imprinting of *FAM50B* and *FAM50B-AS* in the genesis of seminomas also indicates that imprinted expression of this gene needs to be tightly regulated during normal spermatogenesis.

Both segmental duplications and deletions at 6p25 have been associated with diseases and developmental disorders ([@B56; @B57; @B58; @B59]). Genetic loss or gain sometimes detrimentally alters expression of biallelically expressed genes. In contrast, when imprinted genes are present at the location of copy number variation, gene dosage is usually altered dramatically, ranging from complete loss of expression to overexpression. Our finding that the *FAM50B* locus is imprinted stresses the importance of determining parent-of-origin inheritance patterns, in order to better understand the pathogenesis of diseases linked to chromosome location 6p25.
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